Patents by Inventor James W. Edinger

James W. Edinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230355759
    Abstract: Provided herein are populations of placental-derived natural killer cells comprising a cleavage resistant CD16. Also provided are methods of treating diseases, disorders or conditions in a human subject comprising administering to the subject an effective amount of a population of placental-derived natural killer cells comprising a cleavage resistant CD16 to the subject so as thereby to provide an effective treatment of the to the subject. The cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The diseases, disorders or conditions include cancers such as multiple myeloma and lymphoma. The present invention also provides compositions comprising populations of placental-derived natural killer cells comprising a cleavage resistant CD16 for the treatment of a subject and methods of their use.
    Type: Application
    Filed: July 31, 2020
    Publication date: November 9, 2023
    Applicant: CELULARITY INC.
    Inventors: Xuan GUO, Srinivas SOMANCHI, Rohit MATHUR, Shuyang HE, Qian YE, Xiaokui ZHANG, Salvatore ROTONDO, Hemlata RANA, Weifang LING, James W. EDINGER, Robert J. HARIRI, Andrea DIFIGLIA
  • Patent number: 11723930
    Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: August 15, 2023
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
  • Publication number: 20220273716
    Abstract: Provided herein are methods of treating cancer in a human subject comprising administering to the subject an effective amount of human placental-derived natural killer cells comprising a CD38 chimeric antigen receptor (CAR) to the subject so as thereby to provide an effective treatment of the cancer in the subject. The cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The cancers to be treated include multiple myeloma and lymphoma. The present invention also provides compositions comprising human placental-derived natural killer cells comprising a CD38 chimeric antigen receptor (CAR) or the treatment of multiple myeloma and lymphoma and methods of their use.
    Type: Application
    Filed: July 27, 2020
    Publication date: September 1, 2022
    Applicant: Celularity Inc.
    Inventors: Srinivas SOMANCHI, Xuan GUO, Shuyang HE, Rohit MATHUR, Xiaokui ZHANG, Hemlata RANA, Weifang LING, James W. EDINGER, Robert J. HARIRI, Andrea DIFIGLIA
  • Publication number: 20220096564
    Abstract: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
    Type: Application
    Filed: May 13, 2021
    Publication date: March 31, 2022
    Applicant: Celularity Inc.
    Inventors: James W. EDINGER, Robert J. HARIRI, Jia-Lun WANG, Qian YE, Kristen S. LABAZZO, Marian PEREIRA, Sasha Dawn ABRAMSON
  • Publication number: 20220096352
    Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
    Type: Application
    Filed: May 13, 2021
    Publication date: March 31, 2022
    Applicant: Celularity Inc.
    Inventors: Mohit B. BHATIA, Chris LUGO, Qian YE, James W. EDINGER
  • Publication number: 20200397830
    Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
    Type: Application
    Filed: January 24, 2020
    Publication date: December 24, 2020
    Applicant: CELULARITY, INC.
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
  • Patent number: 10590381
    Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: March 17, 2020
    Assignee: Celularity, Inc.
    Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
  • Publication number: 20200048603
    Abstract: Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34+CD45? stem cells from placenta.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 13, 2020
    Applicant: CELULARITY, INC.
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Marian Pereira, Sascha Dawn Abramson, Kristen S. Labazzo
  • Publication number: 20190376027
    Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
    Type: Application
    Filed: August 22, 2019
    Publication date: December 12, 2019
    Applicant: Celularity, Inc.
    Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
  • Patent number: 10494607
    Abstract: Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34+CD45? stem cells from placenta.
    Type: Grant
    Filed: February 12, 2008
    Date of Patent: December 3, 2019
    Assignee: CELULARITY, INC.
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Marian Pereira, Sascha Dawn Abramson, Kristen S. Labazzo
  • Publication number: 20190262406
    Abstract: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
    Type: Application
    Filed: September 21, 2018
    Publication date: August 29, 2019
    Applicant: CELULARITY, INC.
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Kristen S. Labazzo, Marian Pereira, Sascha Dawn Abramson
  • Publication number: 20190089124
    Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
    Type: Application
    Filed: March 14, 2018
    Publication date: March 21, 2019
    Applicant: CELULARITY, INC.
    Inventors: Mohit B. Bhatia, Chris Lugo, Qian Ye, James W. Edinger
  • Patent number: 10105399
    Abstract: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: October 23, 2018
    Assignee: CELULARITY, INC.
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Kristen S. Labazzo, Marian Pereira, Sascha Dawn Abramson
  • Patent number: 9974840
    Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: May 22, 2018
    Assignee: Celularity, Inc.
    Inventors: Mohit Bhatia, Chris Lugo, Qian Ye, James W. Edinger
  • Publication number: 20170327788
    Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
    Type: Application
    Filed: July 28, 2017
    Publication date: November 16, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
  • Patent number: 9775886
    Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: October 3, 2017
    Assignee: Celularity, Inc.
    Inventors: Mohit Bhatia, Chris Lugo, Qian Ye, James W. Edinger
  • Patent number: 9770488
    Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: September 26, 2017
    Assignee: Anthrogenesis Corporation
    Inventors: Mohit Bhatia, Chris Lugo, Qian Ye, James W. Edinger
  • Patent number: 9725694
    Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: August 8, 2017
    Assignee: Anthrogenesis Corporation
    Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
  • Publication number: 20170096473
    Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 6, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: Mohit B. Bhatia, Chris Lugo, Qian Ye, James W. Edinger
  • Patent number: 9598669
    Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: March 21, 2017
    Assignee: Anthrogenesis Corporation
    Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner